Worldwide: Why Combatting Cyber-Crime Is Critical For Life Science Companies

Biotech and pharmaceutical firms hold vast amounts of valuable data and information making them prime targets for cyber-attacks - so how are they protecting themselves?

In the American political thriller series, Homeland, a vice presidential candidate's pacemaker was attacked by offshore terrorists, inducing a heart attack that resulted in his untimely death. In the real world, when Dick Cheney was serving as the 46th vice president of the United States between 2001 and 2009, he famously deactivated the connectivity on his pacemaker so as to prevent anything similar from taking place.

The threat to medical devices may seem like the stuff of science fiction, but in the US, healthcare is now the largest target of cyber security attacks, reportedly at greater risk than manufacturing and banking1. According to experts, the value of stolen personal health information is ten to twenty times greater than the value of a stolen credit card number.

Valuable data

Life science companies hold vast amounts of critically important data and information. Obvious categories include data arising from the development and testing of pharmaceutical products, including clinical trial data, while the rise of biologic drugs has also brought with it valuable manufacturing know-how for these complex molecules.

The sophisticated nature of medical devices and their connectivity raises additional risks. Add in commercially sensitive information about products and their pricing and promotion, and it's no surprise that the sector finds itself the target of cyber-attacks.

Josh Hanet is a senior associate at Gowling WLG, based in Toronto, with a practice focused on medical defence law. He says healthcare cyber security is becoming a significant area of concern for medical device manufacturers and regulators tasked with protecting the public.

"So far, most of the examples in Canada and the US have been ransomware attacks, where hospital networks are attacked and a bitcoin ransom is demanded. There is a potential loss of data, and a risk that hackers have gained access to potentially significant personal health information."

Cyber-attacks as a global issue

In Europe and elsewhere, cyber-attacks are increasing thanks to the growing volume of electronic data and the rising use of electronic storage to keep data. Adding to the problem is the sophistication of cyber criminals.

Helen Davenport is a director based in Gowling WLG's London and Birmingham offices, specialising in technology-related commercial disputes, including cyber-crime and data breaches. She says: "In life sciences, there is an employee threat, where insiders may want to make use of information that they have access to, whether it is intellectual property or personal data.

"Another potential motivation is around sabotage and public profile, where there are people with grudges against pharma companies who want to cause those companies harm by disrupting their businesses and generating bad press."

Key cyber security threats

Patrick Duxbury, partner and head of life sciences with Gowling WLG in the UK, says pharma and biotech companies are concerned about cyber security threats in three key areas:

  • Data relating to clinical trials, and particularly patient data generated during clinical trials. This data is incredibly sensitive at both the patient level and at a commercial level.
  • Corporate know-how and confidential information relating to the manufacture of biologic drugs.
  • Day-to-day commercially sensitive information regarding drug pricing and promotion - a hot topic given the pressures on healthcare budgets around the world.

Duxbury says: "The explosion of large molecule drugs in the last 20 years has created new categories of very valuable information. These drugs are very difficult to make which means companies are very keen to protect their intellectual property and trade secrets. If that information is hacked, or becomes public, that would be incredibly damaging from a commercial point of view. The increasing value of trade secrets has been recognised in both the US and Europe with major legislative changes coming into force this year to enhance the statutory protection available to prevent misuse."

He adds: "Companies see themselves at risk of people hacking into their systems and stealing their know-how, and there has been a huge spike in cyber-attack attempts being made on pharmaceutical systems."

Regulators and cyber security

Regulators have a significant role to play in protecting the public from the impact of cyber security breaches. Both the American Food and Drug Administration (FDA) and European lawmakers have made regular calls for companies to tighten their systems.

The FDA has taken the lead recently in enacting legislation to address manufacturers who fail to properly prevent or rectify a cyber security risk to medical devices.  Failure to comply can now see devices disapproved, recalled, or face regulatory or legal action.

In January 2016, the FDA published draft guidance for the post-market management of cyber security in medical devices, emphasising the need to keep on top of the threat from hackers even after devices have been deployed. The post-market considerations that are critical to the FDA include:

  • Monitoring cyber security information sources for identification and detection of cyber security vulnerabilities and risks;
  • Understanding, assessing and detecting presence and impact of vulnerabilities;
  • Establishing and communicating processes for vulnerability intake and handling;
  • Defining essential clinical performance to develop programs that protect, respond and recover from the cyber security risk;
  • Adopting a coordinated vulnerability disclosure policy and practice; and
  • Deploying mitigations that address cyber security risk early and prior to exploitation.

It has also called for more collaboration between all the various stakeholders in the industry - including the IT community, manufacturers, and clinical users - to combat cyber-crime.

Hanet says: "Many of the regulators around the world are quite reactive, but the FDA is proactive, so we advise clients to look to what the FDA is doing, because where it leads, others often follow. We are seeing obligations now not just when developing devices, but also once they have hit the market. Just like the iPhone gets constantly updated as new threats emerge, now medical devices that have been deployed need to be considered in a similar way."

Information risk management

In the UK, life sciences businesses should be aware of the guidance available that deals with information risk management. For example, the government's information risk management regime puts forward 10 Steps to Cyber Security2 .

The government advises boards to establish an effective governance structure, maintain board engagement with cyber risk, and produce supporting information risk management policies.

"A lot of the guidance is around personnel, training, understanding the threat and having a comprehensive strategy in place to deal with it," says Davenport. "The threat is becoming ever-more sophisticated particularly when it comes to assets such as high-value know-how and clinical data, but equally the statistics show that many incidents involve either insider threats, or employee failure.

"My advice is to start at a fairly basic level with things like user education, network security and mobile working policies, and then develop a strategy to cover more sophisticated threats if necessary, to ensure the crown jewels of your business are protected."

Fragmented legislative framework

The contributions of the FDA and the UK government form just a small part of a legislative framework that is very fragmented, both in terms of laws and standards. An example is ISO 270013, an information security management standard published in October 2005 by the International Organisation for Standardisation.

This standard aims to bring information security under explicit management control so that organisations that have signed up can be formally audited to ensure they are compliant with the standards set. Meanwhile, the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK has also issued draft guidance over medical devices this year to take into account recent developments in apps.

At the European level, the Network and Information Security Directive4, otherwise known as the Cyber Security Directive, entered into force in August 2016, and member states now have 21 months to adopt its rules into national legislation.

Duxbury says: "Cyber security is very much a cross-border issue and this industry is about as international as you can get. There have been attempts across the globe to try to achieve standardisation of approach internationally, but for now companies are faced with a patchwork of legislation, regulations and guidance."

Monitoring the cyber threat

Industry will need to commit more resources to managing cyber risk as the threat continues to evolve. Three large US health insurance firms - Anthem, Premera Blue Cross and UCLA Health - have recently suffered headline-grabbing cyber-attacks concerning patient data.

Indeed, IBM research5 says 100 million medical records were compromised globally in 2015 alone. During the most recent Olympics, the World Anti-Doping Agency said Russian hackers broke into its network and released personal medical records of several top international athletes.

When it comes to the critical area of intellectual property, a PwC survey6 recently found theft of intellectual property (IP) in cyber-attacks on life sciences and pharma companies skyrocketed 176% in 2015, with many stories of hackers selling IP from life sciences firms.

"You mention cyber security and everybody's ears perk up," says Hanet. "It is on their radar, but can become a black hole as you can't possibly be on top of every threat. As technology evolves, so do the threats, often at a pace that is faster than companies can keep track of. From a regulatory perspective, companies are trying to keep ahead of the curve, and from a legal point of view, there's a concern that you are only ever one attack away from significant liability."

For now, best practice centres on the continuous monitoring of the threat, assessing and detecting vulnerability, establishing processes to address weaknesses, adopting disclosure policies, and developing and deploying mitigations when necessary.

For medical devices, the post-market management of risks is becoming as important as the pre-market - particularly if vice presidential health scares are to remain only in the realm of TV dramas.








The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
14 Sep 2017, Seminar, Birmingham, UK

Has Cloud replaced traditional outsourcing models? We will compare cloud to outsourcing, consider whether they have effectively become the same thing for many solutions and assess some of the advantages and disadvantages of each model.

18 Sep 2017, Seminar, London, UK

Our annual event as part of the London Design Festival is now in its fifth year. We would be delighted if you are able to join us again.

21 Sep 2017, Seminar, London, UK

Has Cloud replaced traditional outsourcing models? We will compare cloud to outsourcing, consider whether they have effectively become the same thing for many solutions and assess some of the advantages and disadvantages of each model.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.